Roche Holding AG (SW:ROG) — Market Cap & Net Worth
Market Cap & Net Worth: Roche Holding AG (ROG)
Roche Holding AG (SW:ROG) has a market capitalization of $279.33 Billion (CHF220.94 Billion) as of April 27, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #60 globally and #1 in its home market, demonstrating a -8.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Roche Holding AG's stock price CHF320.70 by its total outstanding shares 688926637 (688.93 Million).
Roche Holding AG Market Cap History: 2015 to 2026
Roche Holding AG's market capitalization history from 2015 to 2026. Data shows growth from $178.94 Billion to $279.33 Billion (4.97% CAGR).
Index Memberships
Roche Holding AG is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.09 Trillion | 3.94% | #2 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.09 Trillion | 3.94% | #2 of 182 |
Weight: Roche Holding AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Roche Holding AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Roche Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.65x
Roche Holding AG's market cap is 4.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.19x
Roche Holding AG's market cap is 22.19 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $155.35 Billion | $52.64 Billion | $9.58 Billion | 2.95x | 16.22x |
| 2017 | $170.04 Billion | $55.75 Billion | $8.63 Billion | 3.05x | 19.70x |
| 2018 | $174.24 Billion | $59.50 Billion | $10.50 Billion | 2.93x | 16.59x |
| 2019 | $231.97 Billion | $63.75 Billion | $13.50 Billion | 3.64x | 17.19x |
| 2020 | $235.59 Billion | $58.32 Billion | $14.29 Billion | 4.04x | 16.48x |
| 2021 | $297.74 Billion | $62.80 Billion | $13.93 Billion | 4.74x | 21.37x |
| 2022 | $234.25 Billion | $65.81 Billion | $12.42 Billion | 3.56x | 18.86x |
| 2023 | $204.47 Billion | $60.44 Billion | $11.50 Billion | 3.38x | 17.78x |
| 2024 | $222.54 Billion | $62.40 Billion | $8.28 Billion | 3.57x | 26.89x |
| 2025 | $285.86 Billion | $61.52 Billion | $12.88 Billion | 4.65x | 22.19x |
Competitor Companies of ROG by Market Capitalization
Companies near Roche Holding AG in the global market cap rankings as of April 27, 2026.
Key companies related to Roche Holding AG by market ranking:
- Eli Lilly and Company (SA:LILY34): Ranked #16 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Eli Lilly and Company (NYSE:LLY): Ranked #18 globally with a market cap of $791.16 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #22 globally with a market cap of $548.11 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #39 globally with a market cap of $351.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #18 | Eli Lilly and Company | NYSE:LLY | $791.16 Billion | $883.96 |
| #22 | Johnson & Johnson | NYSE:JNJ | $548.11 Billion | $227.50 |
| #39 | AbbVie Inc | NYSE:ABBV | $351.35 Billion | $198.71 |
Roche Holding AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Roche Holding AG's market cap moved from $178.94 Billion to $ 279.33 Billion, with a yearly change of 4.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF279.33 Billion | -2.29% |
| 2025 | CHF285.86 Billion | +28.45% |
| 2024 | CHF222.54 Billion | +8.83% |
| 2023 | CHF204.47 Billion | -12.71% |
| 2022 | CHF234.25 Billion | -21.33% |
| 2021 | CHF297.74 Billion | +26.38% |
| 2020 | CHF235.59 Billion | +1.56% |
| 2019 | CHF231.97 Billion | +33.13% |
| 2018 | CHF174.24 Billion | +2.47% |
| 2017 | CHF170.04 Billion | +9.46% |
| 2016 | CHF155.35 Billion | -13.18% |
| 2015 | CHF178.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 26th, 2026 the market cap of Roche Holding AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $279.33 Billion USD |
| MoneyControl | $279.33 Billion USD |
| MarketWatch | $279.33 Billion USD |
| marketcap.company | $279.33 Billion USD |
| Reuters | $279.33 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more